The compilation is based on forecasts from Evaluate Vantage, whose analysts have assessed which anticipated blockbusters may receive FDA approval during the year, and how much annual revenue these products are estimated to generate six years later, in 2032.
The list is topped by the two major rivals in the obesity field: Novo Nordisk and Eli Lilly. Their drug candidates, Cagrisema and orforglipron respectively, are expected to generate USD 17.2 billion and USD 11.8 billion in 2032.
BREAKING